OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Inside the Clinic: Acute Graft-versus-Host Disease

home / insights / acute-graft-versus-host-disease
Site Logo

EP. 1: Graft-Vs-Host Disease Explored

August 2nd 2019
Site Logo

EP. 2: Classifying GVHD and Predicting Risk of Events

August 2nd 2019
Acute Graft-Vs-Host Disease: Risk Factors

EP. 3: Acute Graft-Vs-Host Disease: Risk Factors

August 2nd 2019
Site Logo

EP. 4: Approaching Acute Graft-Vs-Host Disease

August 2nd 2019
Treating Acute GVHD: Systemic Corticosteroids

EP. 5: Treating Acute GVHD: Systemic Corticosteroids

August 2nd 2019
Managing Steroid-Refractory Acute GVHD

EP. 6: Managing Steroid-Refractory Acute GVHD

August 2nd 2019
Ruxolitinib for Steroid-Refractory Acute GVHD

EP. 7: Ruxolitinib for Steroid-Refractory Acute GVHD

August 2nd 2019
Implications for Treating Acute GVHD With Ruxolitinib

EP. 8: Implications for Treating Acute GVHD With Ruxolitinib

August 2nd 2019
Fecal Microbiota Transplantation for Acute GVHD

EP. 9: Fecal Microbiota Transplantation for Acute GVHD

August 2nd 2019
Novel-Based Approaches and the Future of Acute GVHD

EP. 10: Novel-Based Approaches and the Future of Acute GVHD

August 2nd 2019
What is Acute Graft-Versus-Host Disease?

EP. 11: What is Acute Graft-Versus-Host Disease?

August 2nd 2019
Acute GVHD: Grade, Risk, and Prophylaxis

EP. 12: Acute GVHD: Grade, Risk, and Prophylaxis

August 2nd 2019
Frontline Management of Acute Graft-Versus-Host Disease

EP. 13: Frontline Management of Acute Graft-Versus-Host Disease

August 2nd 2019
Second-Line Management of Acute Graft-Versus-Host Disease

EP. 14: Second-Line Management of Acute Graft-Versus-Host Disease

August 2nd 2019
Treating Acute GVHD With Novel Strategies

EP. 15: Treating Acute GVHD With Novel Strategies

August 2nd 2019
Acute GVHD: An Evolving Treatment Paradigm

EP. 16: Acute GVHD: An Evolving Treatment Paradigm

August 2nd 2019

Latest Conference Coverage

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact